Elevai Labs announced results from an on-going research study in partnership with Dr. Stanislav Sokolenko’s Lab, Associate Professor at Dalhousie University’s Department of Process Engineering and Applied Science, demonstrating the potential of its proprietary Precision Regenerative Exosome Technology in generating exosomes that carry proteins associated with extracellular matrix organization, immune functions, and wound healing. “In this study, we were trying to answer whether our exosomes were fundamentally different than exosomes from other sources,” stated Company Chief Executive Officer Jordan Plews. “The data has led us to believe that, when appropriately processed through our PREx platform, our ethically sourced human umbilical cord-derived mesenchymal stem cells release exosomes enriched with a profile of proteins similar to, but distinct from, other mesenchymal stem cell sources.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAB:
- Elevai Labs reports Q2 revenue $605,529
- Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
- Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD
- Elevai Labs subsidiary appoints Shirihai to Scientific Advisory Board
- ELEVAI Labs Shares Future Direction and Financial Outlook